Biotech Briefing: AGTC and Otonomy Collaborate to Develop Gene Therapy for Congenital Hearing Loss

Reports + Research AGTC and Otonomy Collaborate to Develop Gene Therapy for Congenital Hearing Loss Applied Genetic Technologies Corporation (AGTC) and Otonomy formed a collaboration to co-develop and co-commercialize an adeno-associated virus (AAV)-based gene therapy that could potentially restore hearing in patients with hearing loss caused by a mutation in the gap junction protein beta …

The post Biotech Briefing: AGTC and Otonomy Collaborate to Develop Gene Therapy for Congenital Hearing Loss appeared first on Hatch.